Evidence map›Paper›PMID 11665864›Full record

ArticleJournal of molecular neuroscience : MN2001

Dysferlin protein analysis in limb-girdle muscular dystrophies.

M Vainzof, L V Anderson, E M McNally, D B Davis, G Faulkner, G Valle, E S Moreira, R C Pavanello, M R Passos-Bueno, M Zatz

Registry-linked trialOpen access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular neuroscience : MN, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00138931 (Genetic Studies of Patients and Their Families With Inherited Cardiovascular and Neuromuscular Diseases.), which is not on this map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00138931 recruitingnot on this map

Genetic Studies of Patients and Their Families With Inherited Cardiovascular and Neuromuscular Diseases.

TypeobservationalSponsorUniversity of ChicagoRan1996 to 2030Enrolled2,000ConditionsCardiomyopathy, Arrhythmia, Muscular DystrophyArmsBlood draw (genetic testing)
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 85 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Atypical Miyoshi distal myopathy: A case report.Experimental and therapeutic medicine · 2016
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Dysferlinopathy course and sportive activity: clues for possible treatment.Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology · 2011
    Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 4 countries.

M VainzofCentro de Estudos do Genoma Humano, Dept. Biology, IB, Universidade de São Paulo, Brazil. mvainzof@usp.br
L V Anderson
E M McNally
D B Davis
G Faulkner
G Valle
E S Moreira
R C Pavanello
M R Passos-Bueno
M Zatz
Universidade de São Paulo · BRUniversity of Chicago · USCentro de Estudos da Voz · BRInternational Centre for Genetic Engineering and Biotechnology · ITNewcastle University · GBUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dysferlin is the protein product of the DYSF gene mapped at 2p31, which mutations cause limb-girdle muscular dystrophy type 2B (LGMD2B) and Miyoshi myopathy. To date, nine autosomal recessive forms (AR-LGMD) have been identified: four genes, which code for the sarcoglycan glycoproteins, are associated with both mild and severe forms, the sarcoglycanopathies (LGMD2C, 2D, 2E and 2F). The other five forms, usually causing a milder phenotype are LGMD2A (calpain 3), LGMD2B (dysferlin), LGMD2G (telethonin), LGMD2H (9q31-11), and LGMD21 (19q13.3). We studied dysferlin expression in a total of 176 patients, from 166 LGMD families: 12 LGMD2B patients, 70 with other known forms of muscular dystrophies (LGMD2A, sarcoglycanopathies, LGMD2G), in an attempt to assess the effect of the primary gene-product deficiency on dysferlin. In addition, 94 still unclassified LGMD families were screened for dysferlin deficiency. In eight LGMD2B patients from five families, no dysferlin was observed in muscle biopsies, both through immunofluorescence (IF) and Western blot methodologies, while in two families, a very faint band was detected. Both patterns, negative or very faint bands, were concordant in patients belonging to the same families, suggesting that dysferlin deficiency is specific to LGMD2B. Myoferlin, the newly identified homologue of dysferlin was studied for the first time in LGMD2B patients. Since no difference was observed between patients mildly and severely affected, this protein do not seem to modify the phenotype in the present dysferlin-deficient patients. Dystrophin, sarcoglycans, and telethonin were normal in all LGMD2B patients, while patients with sarcoglycanopathies (2C, 2D, and 2E), LGMD2A, LGMD2G, and DMD showed the presence of a normal dysferlin band by Western blot and a positive pattern on IF. These data suggest that there is no interaction between dysferlin and these proteins. However, calpain analysis showed a weaker band in four patients from two families with intra-familial concordance. Therefore, this secondary deficiency of calpain in LGMD2B families, may indicate an interaction between dysferlin and calpain in muscle. Dysferlin was also present in cultured myotubes, in chorionic villus, and in the skin. Dysferlin deficiency was found in 24 out of a total of 166 Brazilian AR-LGMD families screened for muscle proteins (approximately 14%), thus representing the second most frequent known LGMD form, after calpainopathy, in our population.

Indexed as

Membrane ProteinsAdultAge of OnsetCalcium-Binding ProteinsCalpainChildConnectinDysferlinDystrophinFemaleGenetic LinkageHumansImmunohistochemistryMaleMiddle AgedMuscle ProteinsCalcium-Binding ProteinsCalpainConnectinDysferlinDYSF protein, humanDystrophinMembrane ProteinsMuscle ProteinsMYOF protein, humanPolysaccharidesTCAP protein, human

Identifiers

PMID11665864
OpenAlexW2086252337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.